Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alzheimer's disease vaccine (recombinant protein) + Advax
- Development stage
- Unknown
- Lead developer
- Vaxine
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This experimental Alzheimer's disease vaccine is a recombinant protein-based immunotherapy developed by Vaxine in collaboration with the Institute of Molecular Medicine and the University of California, Irvine. Utilizing the MultiTEP platform, the vaccine is designed to target pathological proteins associated with Alzheimer's, specifically amyloid-beta (Aβ) and tau. The formulation includes Vaxine's proprietary Advax adjuvant (specifically AdvaxCpG, a delta inulin-based adjuvant), which enhances the immune response to elicit high-titer antibodies. These antibodies are intended to reduce the accumulation of pathological protein aggregates in the brain, offering both potential preventive and therapeutic benefits. Specific candidates within this program include AV-1959R (targeting Aβ), AV-1980R (targeting tau), and the dual-specificity vaccine AV-1953R.
- Other names
- amyloid/tau recombinant protein + AdvaxMultiTEP Alzheimer's vaccine
02
Targets
MAPT (Microtubule-associated protein tau)Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on alzheimer's disease vaccine (recombinant protein) + Advax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alzheimer's disease vaccine (recombinant protein) + Advax.